Nargenicin enhances 1,25-dihydroxyvitamin D-3- and all-trans retinoic acid-induced leukemia cell differentiation via PKC beta I/MAPK pathways
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seung Hyun | - |
dc.contributor.author | Yoo, Jin Cheol | - |
dc.contributor.author | Kim, Tae Sung | - |
dc.date.accessioned | 2021-09-08T16:14:58Z | - |
dc.date.available | 2021-09-08T16:14:58Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2009-06-01 | - |
dc.identifier.issn | 0006-2952 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/119840 | - |
dc.description.abstract | A major goal in the treatment of acute myeloid leukemia (AML) is to achieve terminal differentiation and prevent drug resistance and side effects. Combined treatment with low doses of ATRA or 1,25-(OH)(2)D-3 that do not induce toxicity with another drug is one useful strategy for the treatment of AML. Actinomycetes are the well known sources of antibiotics and bioactive molecules. Previously, we isolated nargenicin from the culture broth of an actinomycete isolate, Nocardia sp. CS682. In this study, we evaluated the effects of nargenicin on cellular differentiation in a human myeloid leukemia HL-60 cell system. Nargenicin inhibited cell proliferation and induced HL-60 cell differentiation when administered in combination with 1,25-(OH)(2)D-3 or ATRA. In addition, western blot analyses and kinase inhibitor studies demonstrated that nargenicin primarily enhanced leukemia cell differentiation via PKC beta 1/MAPK pathways. The results of this study indicate that nargenicin has the ability to induce differentiation and suggest that it may be useful for the treatment of neoplastic diseases. (c) 2009 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | ACUTE PROMYELOCYTIC LEUKEMIA | - |
dc.subject | MYELOID-LEUKEMIA | - |
dc.subject | VITAMIN-D | - |
dc.subject | SESQUITERPENE LACTONE | - |
dc.subject | HL-60 CELLS | - |
dc.subject | HL60 CELLS | - |
dc.subject | THERAPY | - |
dc.subject | ACTIVATION | - |
dc.subject | INHIBITOR | - |
dc.subject | ARREST | - |
dc.title | Nargenicin enhances 1,25-dihydroxyvitamin D-3- and all-trans retinoic acid-induced leukemia cell differentiation via PKC beta I/MAPK pathways | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Tae Sung | - |
dc.identifier.doi | 10.1016/j.bcp.2009.03.004 | - |
dc.identifier.scopusid | 2-s2.0-64249148822 | - |
dc.identifier.wosid | 000265768300005 | - |
dc.identifier.bibliographicCitation | BIOCHEMICAL PHARMACOLOGY, v.77, no.11, pp.1694 - 1701 | - |
dc.relation.isPartOf | BIOCHEMICAL PHARMACOLOGY | - |
dc.citation.title | BIOCHEMICAL PHARMACOLOGY | - |
dc.citation.volume | 77 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1694 | - |
dc.citation.endPage | 1701 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ACUTE PROMYELOCYTIC LEUKEMIA | - |
dc.subject.keywordPlus | MYELOID-LEUKEMIA | - |
dc.subject.keywordPlus | VITAMIN-D | - |
dc.subject.keywordPlus | SESQUITERPENE LACTONE | - |
dc.subject.keywordPlus | HL-60 CELLS | - |
dc.subject.keywordPlus | HL60 CELLS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | ARREST | - |
dc.subject.keywordAuthor | Nargenicin | - |
dc.subject.keywordAuthor | Cell differentiation | - |
dc.subject.keywordAuthor | 1,25-Dihydroxyvitamin D-3 | - |
dc.subject.keywordAuthor | All-trans retinoic acid | - |
dc.subject.keywordAuthor | Protein kinase C | - |
dc.subject.keywordAuthor | Mitogen-activated protein kinase | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.